Sunday, 14 December 2025
  
Login

Australia's most trusted
source of pharma news

Sunday, 14 December 2025
News

Sanofi v Amgen for $30m market

Posted 27 October 2022 PM

Sanofi has taken its battle for the PCSK9 market to the Federal Court, targeting the patents underlying Amgen's cholesterol-lowering antibody Repatha.

Repatha was the first PCSK9 inhibitor to be listed on the PBS, back in December 2016, for homozygous familial hypercholesterolaemia. In November 2018 it had that indication extended to include heterozygous familial hypercholesterolaemia.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (3)

Sales & Customer Relations (11)

Clinical & Medical, R&D (9)

Regulatory, Pharmacovigilance & QA (1)

Devices (1)

Other (11)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.